actualment
planteada
en
el
desarrollo
de
ensayo
con
lo
diferent
tipo
de
vacuna
palabra
clave
vih
sida
vacuna
mecanismo
de
escap
viral
inmunidad
antivir
uncontrol
progress
aid
epidem
made
develop
efficaci
human
immunodefici
viru
hiv
vaccin
major
object
scientif
research
effect
prevent
vaccin
hiv
current
avail
steril
immun
yet
achiev
anim
model
review
analys
major
challeng
develop
aid
vaccin
particular
mechan
involv
viral
escap
immun
respons
summar
result
obtain
differ
prototyp
therapeut
prevent
vaccin
final
social
econom
healthcar
aspect
research
hiv
vaccin
current
controversi
regard
develop
clinic
trial
discuss
enferm
infecc
microbiol
clin
supl
enferm
infecc
microbiol
clin
supl
j
et
al
current
situat
develop
prevent
hiv
vaccin
year
aid
pandem
respons
three
million
death
five
million
peopl
calcul
contract
viru
period
take
number
infect
peopl
throughout
world
million
million
death
regist
sinc
origin
pandem
identifi
geograph
econom
differ
diseas
obviou
case
death
aid
occur
third
world
africa
especi
among
young
adult
gradual
increas
women
dramat
see
subsaharian
africa
epidem
continu
spread
mani
countri
high
percentag
peopl
infect
aid
devast
effect
famili
product
economi
explos
epidem
develop
countri
rais
need
take
urgent
prevent
measur
provid
expand
access
antiretrovir
therapi
howev
part
world
measur
although
essenti
probabl
insuffici
curb
epidem
develop
vaccin
avail
possibl
control
therefor
develop
efficaci
hiv
vaccin
area
aid
research
yet
resolv
also
urgent
need
develop
countri
awar
led
consider
increas
financ
search
aid
vaccin
obtain
effect
hiv
vaccin
repres
major
challeng
prioriti
scientif
object
public
privat
institut
govern
ngo
tabl
chapter
analys
prototyp
vaccin
develop
result
obtain
scientif
difficulti
develop
vaccin
especi
regard
mechan
viral
escap
immun
respons
furthermor
research
set
social
econom
healthcar
context
aid
pandem
current
controversi
surround
clinic
trial
differ
type
vaccin
address
review
actual
en
el
desarrollo
de
una
vacuna
preventiva
frent
al
vih
el
avanc
de
la
epidemia
de
sida
ha
convertido
la
de
una
vacuna
eficaz
frent
al
viru
de
la
inmunodeficiencia
humana
vih
como
un
objetivo
prioritario
en
el
momento
actual
disponemo
de
una
vacuna
preventiva
frent
la
por
el
vih
en
modelo
anim
se
ha
conseguido
la
frent
la
en
esta
se
analizan
la
dificultad
existent
en
el
desarrollo
de
una
vacuna
contra
el
sida
en
especi
lo
mecanismo
de
escap
viral
la
respuesta
inmunitaria
se
describen
lo
prototipo
de
vacuna
preventiva
en
desarrollo
lo
resultado
obtenido
por
otra
part
se
esta
en
el
contexto
sanitario
social
de
la
pandemia
de
sida
se
analizan
la
order
develop
vaccin
necessari
know
gene
pathogen
involv
induct
specif
immun
respons
use
experiment
model
test
efficaci
viru
despit
fact
past
import
advanc
control
infecti
diseas
vaccin
mani
mechan
use
pathogen
take
cell
machineri
unknown
appli
mechan
escap
immun
system
way
boost
immun
respons
capabl
elimin
infect
cell
scientif
term
obtain
efficaci
vaccin
capabl
prevent
hiv
infect
face
seri
challeng
immun
respons
begin
recognit
lymphocyt
via
receptor
tcr
foreign
antigen
classii
hla
groov
present
cell
special
antigen
process
antigen
recognit
activ
differ
effector
mechan
immun
system
cytokin
chemokin
synthesi
product
antibodi
b
lymphocyt
activ
lymphocyt
gener
cytotox
lymphocyt
last
event
repres
main
mechan
involv
kill
virusinfect
cell
initi
process
cytotox
lymphocyt
must
recogn
antigen
determin
viru
lodg
classi
hla
groov
infect
cell
consequ
polymorph
hla
system
antigen
present
cell
target
cell
differ
peptid
anchor
class
ii
class
hla
molecul
respect
select
accord
individu
hla
haplotyp
mani
virus
major
immunodomin
determin
epitop
induc
potent
respons
immun
system
efficaci
respons
depend
two
characterist
first
correspond
epitop
domain
viral
protein
conserv
among
differ
isol
even
context
highli
variabl
virus
second
major
determin
capabl
bind
groov
hla
haplotyp
exist
identif
major
immunogen
determin
crucial
develop
vaccin
sinc
make
viral
target
par
excel
univers
two
sens
epitop
conserv
viral
protein
among
differ
isol
epitop
suscept
antigen
present
subject
regardless
hla
haplotyp
howev
case
hiv
similar
domin
epitop
found
date
repres
import
limit
design
vaccin
presenc
major
immunogen
determin
virus
tremend
genet
variabl
make
practic
imposs
defin
epitop
empir
experiment
nevertheless
bioinformat
provid
us
predict
method
make
identif
easier
object
vaccin
induc
efficaci
memorytyp
immun
respons
allow
immun
system
react
infecti
agent
prevent
spread
object
reach
essenti
know
immunolog
effector
efficaci
control
infect
order
defin
seri
surrog
immunolog
paramet
enabl
us
evalu
whether
vaccin
prepar
effici
intens
immun
respons
hivinfect
patient
report
encompass
practic
effector
mechan
immun
system
respons
rel
wide
sinc
develop
numer
epitop
practic
viral
protein
structur
regulatori
recogn
foreign
antigen
howev
controversi
still
surround
role
protect
play
compon
antivir
respons
describ
type
immun
respons
gener
hiv
infect
hiv
infect
induc
intens
antibodi
respons
practic
regulatori
structur
protein
hiv
antibodi
neutral
capac
vitro
vivo
adopt
immunotherapi
experi
howev
product
antibodi
neutral
capac
scarc
viral
escap
antibodi
rapid
furthermor
immun
model
develop
date
high
level
neutral
antibodi
consist
obtain
presenc
systemat
associ
protect
data
rais
sever
concern
role
humor
respons
control
hiv
infect
nevertheless
almost
prevent
vaccin
induc
neutral
antibodi
role
surrog
protect
marker
clearli
demonstr
diseas
therefor
priori
prevent
hiv
vaccin
induc
broadspectrum
neutral
antibodi
one
huge
challeng
current
face
develop
aid
vaccin
recent
studi
defin
loca
tion
neutral
epitop
antibodi
structur
mechan
action
repres
import
advanc
defin
characterist
given
vaccin
must
induc
neutral
antibodi
studi
agre
combin
respons
probabl
import
protect
mechan
hiv
studi
cellular
respons
shown
seroposit
patient
clonal
expans
lymphocyt
activ
hiv
expans
particularli
intens
patient
primari
infect
correl
control
viral
replic
also
report
show
intens
respons
patient
immun
reconstitut
antiretrovir
therapi
especi
good
immunolog
statu
start
therapi
phenomenon
describ
patient
structur
treatment
interrupt
spontan
control
viral
replic
although
difficult
draw
conclus
causeeffect
relationship
appear
specif
type
immun
respons
control
viral
replic
data
seem
suggest
helper
cytotox
immun
respons
essenti
contain
viral
replic
earli
stage
diseas
immun
system
rel
undamag
conclus
experiment
data
role
cellular
respons
control
viral
replic
come
studi
select
deplet
lymphocyt
macaqu
infect
siv
lead
huge
increas
viremia
acceler
evolut
aid
hiv
transmiss
occur
mainli
via
mucosa
larg
quantiti
lymphocyt
genitorect
lymphoid
tissu
repres
major
reservoir
replic
hiv
siv
even
infect
contract
intraven
gutassoci
lymphoid
tissu
system
galt
set
activ
b
lymphocyt
dendrit
cell
migrat
lymphat
system
bloodstream
distant
lymph
node
becom
resid
thu
induct
strong
immun
respons
mucosa
probabl
necessari
requir
vaccin
effici
hiv
famili
virus
develop
differ
escap
mechan
avoid
elimin
immun
system
vaccin
must
face
escap
mechan
success
must
induc
seri
immun
respons
capabl
overcom
rate
variabl
hiv
due
high
error
rate
revers
transcriptas
one
substitut
per
nucleotid
round
copi
consequ
wide
intersubtyp
intrasubtyp
variabl
immunolog
relev
vaccin
design
genet
dispar
matter
debat
sever
investig
shown
genet
differ
among
hiv
subtyp
correl
immunotyp
fact
sever
genet
subtyp
could
share
common
protect
epitop
one
immunotyp
found
genet
subtyp
gener
neutral
antibodi
seem
strainspecif
wherea
cellular
immun
respons
broader
spectrum
lack
fidel
gener
high
divers
viral
protein
allow
escap
control
specif
immun
respons
therefor
hiv
share
rna
virus
common
escap
mechan
relat
high
variabl
allow
viru
find
hole
immun
repertoir
togeth
variabl
gener
high
error
rate
revers
transcriptas
mechan
genet
recombin
produc
new
subtyp
mosaic
virus
among
differ
subtyp
also
involv
gener
hiv
variant
sever
molecular
epidemiolog
studi
stress
rapid
dissemin
hiv
variant
describ
distribut
sever
subtyp
recombin
virus
differ
part
world
could
obstacl
develop
univers
vaccin
one
central
aspect
hiv
infect
total
understood
reason
viral
replic
control
despit
potent
immun
respons
elicit
primari
infect
although
sever
explan
put
forward
wide
report
viral
escap
mutat
viral
epitop
recogn
differ
effector
mechan
immun
system
escap
ctl
respons
due
ad
hoc
mutat
viral
epitop
interact
groov
hla
molecul
shown
mutat
critic
residu
gener
viral
escap
anim
model
patient
primari
infect
event
result
loss
ctl
respons
parallel
increas
viremia
howev
chronic
phase
infect
clear
correl
presenc
specif
ctl
elimin
persist
given
viral
variant
addit
mere
quantit
data
function
analysi
shown
qualit
differ
ctl
progressor
nonprogressor
express
perforin
product
cytokin
chemokin
reduc
activ
tcell
receptor
viral
epitop
present
hla
complex
data
suggest
qualit
aspect
ctl
may
also
import
control
viral
replic
gener
strategi
maxim
efficaci
vaccin
would
obtain
cytotox
respons
larg
number
epitop
sever
protein
howev
recent
studi
suggest
target
approach
effect
thu
ctl
nonstructur
protein
tat
nef
effici
control
infect
prone
viral
escap
last
long
ctl
structur
protein
gag
pol
steril
vaccin
object
would
induc
intens
ctl
respons
earli
protein
wherea
immun
structur
protein
would
gener
respons
would
control
viral
replic
thu
attenu
infect
anoth
problem
may
seriou
genet
resist
barrier
adapt
viru
hla
haplotyp
infect
patient
situat
peptid
viral
mutant
gener
would
reduc
affin
hla
thu
decreas
recognit
tcr
gener
greater
resist
ctl
respons
structur
viral
envelop
nativ
form
hide
domain
interact
viral
coreceptor
due
trimer
structur
fold
protein
oligomer
exclus
entrop
mask
exposur
conserv
epitop
identifi
neutral
antibodi
take
place
moment
interact
viral
cellular
membran
set
antibodi
efficaci
lower
given
low
access
neutral
epitop
second
classic
escap
mechan
epitop
mutat
hypervari
region
found
extern
domain
viral
envelop
nevertheless
recent
studi
show
escap
antibodi
alway
requir
mutat
amino
acid
residu
take
place
glycosyl
residu
format
carbohydr
structur
viral
known
glycan
shield
repres
authent
barrier
action
neutral
antibodi
one
spectacular
studi
publish
last
year
show
evolut
specif
patient
viral
envelop
gradual
becom
resist
type
neutral
neutral
antibodi
via
accumul
previous
mention
escap
mechan
anim
model
patient
primari
infect
sexual
contact
establish
hiv
infect
rapid
process
hour
lymphoid
cell
rectal
vagin
submucosa
becom
infect
seven
day
infect
spread
system
lymph
node
reach
viral
provir
load
similar
level
found
chronic
infect
speed
reservoir
appear
specif
immun
respons
trigger
repres
major
obstacl
control
viral
replic
sinc
establish
hiv
infect
persist
lymphocyt
despit
immun
respons
hiv
infect
target
cell
latent
form
situat
viral
protein
express
membran
infect
cell
thu
allow
escap
immun
surveil
furthermor
reactivationreinfect
process
take
place
lymphoid
organ
provid
ideal
cellular
microenviron
process
infect
dendrit
cell
express
membran
lectin
dcsign
interact
virion
lymphocyt
enhanc
hiv
infect
antigen
recognit
lymphocyt
presenc
cytokin
microenviron
turn
increas
infect
target
cell
promot
viral
replic
confirm
data
hivspecif
lymphocyt
clone
shown
infect
higher
proport
impli
preferenti
immunosuppress
hivspecif
respons
must
stress
continu
gener
new
latent
infect
cell
activ
viral
replic
compart
gener
continu
archiv
chang
produc
viru
throughout
diseas
includ
treatmentresist
mutat
genom
variant
immun
escap
latent
compart
therefor
static
way
hiv
store
histori
latent
infect
cell
thu
contribut
viral
divers
mechan
escap
antiretrovir
therapi
vaccin
attenu
viru
vaccin
without
doubt
efficaci
germ
carri
limit
seri
replic
cycl
simul
lowlevel
infect
induc
whole
spectrum
antivir
respons
physiolog
set
case
lentivirus
one
spectacular
find
show
defect
nefdelet
siv
viru
induc
protect
respons
challeng
highli
pathogen
aggress
viabl
virus
experiment
data
natur
correl
sydney
cohort
made
patient
infect
blood
transfus
seroposit
donor
year
infect
excel
clinic
immunolog
statu
clone
character
viru
patient
donor
show
present
delet
nef
gene
critic
regulatori
sequenc
ltr
region
find
led
propos
attenu
hiv
vaccin
similar
defect
siv
mutant
howev
must
stress
attenu
vaccin
usual
use
virus
persist
altern
attenu
viru
use
vaccin
capabl
persist
host
case
nefdefect
virus
infect
also
replic
persist
host
risk
drift
toward
aggress
variant
vaccin
subject
first
alarm
data
came
vaccin
newborn
maca
que
contrast
found
adult
innocu
viru
rapidli
induc
aggress
infect
death
immunodefici
furthermor
prolong
followup
patient
sydney
cohort
enabl
us
observ
immunolog
deterior
blip
viremia
subject
similarli
adult
maca
que
vaccin
defect
siv
viru
develop
aid
viru
vaccin
suffer
revers
mutant
phenotyp
therefor
use
vaccin
defect
virus
rule
approach
explicitli
exclud
guidelin
recommend
regulatori
agenc
inactiv
virus
scarc
use
prevent
vaccin
contrari
wide
use
model
therapeut
vaccin
remun
prototyp
viral
prepar
compos
complet
virion
particl
whose
envelop
elimin
inactiv
use
differ
chemic
method
administ
conjunct
freund
incomplet
adjuv
first
hiv
vaccin
base
hepat
b
immun
model
compos
recombin
protein
gp
gp
produc
genet
engin
use
vaccinia
viru
express
vector
preclin
studi
phase
phase
ii
clinic
trial
prepar
safe
induc
antibodi
synthesi
viral
envelop
antibodi
incap
neutral
wildtyp
variant
vitro
spite
evid
efficaci
prototyp
phase
iii
trial
continu
see
trial
use
regulatori
protein
tat
toxoid
form
provid
good
protect
result
macaqu
studi
although
role
remain
controversi
peptid
vaccin
littl
immunogen
capac
sinc
mani
case
antibodi
recogn
primari
structur
aminoacid
sequenc
rather
secondari
tertiari
structur
target
protein
simul
peptid
therefor
peptid
gener
use
combin
vaccin
prepar
viral
vector
dna
order
induc
complementari
immun
advantag
combin
low
toxic
possibl
prepar
peptid
cocktail
cover
wide
rang
viral
isol
protein
present
high
variabl
use
mix
peptid
includ
b
immunodomin
epitop
induc
cellular
humor
respons
system
use
virus
bacteria
whose
genom
hiv
gene
insert
way
protein
express
cours
replic
vector
host
cell
develop
model
use
poxviru
vaccinia
canarypox
modifi
ankara
virusmva
adenoviru
experiment
approach
use
bacteria
bcg
salmonella
rna
virus
coronaviru
vsv
sfv
reoviru
polioviru
influenza
includ
also
lentiviru
system
limit
risk
exogen
genet
inform
vector
integr
host
genom
advantag
viral
bacteri
system
lie
possibl
insert
sever
viral
gene
genom
capac
express
high
level
viral
protein
strong
antigen
express
turn
induc
potent
prolong
immun
stimul
particularli
cellular
immun
respons
protein
vaccin
prototyp
current
develop
includ
gene
gag
pol
env
nef
differ
combin
differ
primingboost
strategi
vaccin
dose
type
prepar
fail
prevent
vaccin
anim
model
sinc
achiev
protect
immun
probabl
due
fact
humor
respons
induc
hiv
protein
errat
reduc
potenc
howev
induc
potent
cellular
respons
make
viral
load
stabil
low
level
optimist
scenario
suggest
respons
could
enough
attenu
infect
transform
vaccin
patient
becom
infect
longterm
survivor
new
vector
bcg
salmonella
polioviru
expect
induc
greater
humor
cellular
immun
mucosa
mean
oral
administr
thu
improv
efficaci
vaccin
observ
nake
dna
capabl
induc
immun
respons
sever
virus
differ
anim
model
broke
new
ground
develop
vaccin
infect
model
siv
shiv
observ
microbi
vector
immun
dna
capabl
induc
immun
respons
although
protect
infect
often
attenu
viral
replic
clinic
symptom
main
limit
dna
vector
intens
immun
respons
induc
low
therefor
gener
use
combin
viral
vector
disadvantag
type
vaccin
potenti
longterm
secondari
effect
owe
chromosom
integr
process
adjuv
prepar
boost
immun
respons
vaccin
antigen
differ
mechan
tradit
adjuv
freund
bacteri
lysat
induc
nonspecif
inflammatori
respons
recruit
immun
cell
inject
site
other
iscom
liposom
improv
present
antigen
recent
studi
demonstr
efficaci
interleukin
especi
activ
respons
interleukin
chemokin
boost
respons
induc
attenuatedvector
nakeddna
vaccin
success
inocul
interv
week
use
two
differ
vector
express
hiv
antigen
primeboost
shown
induc
stronger
cellular
immun
respons
hiv
antigen
vector
administ
two
dose
procedur
boost
specif
cell
induct
develop
murin
malaria
system
show
increas
correl
protect
pathogen
one
best
system
report
base
recombin
poxvirus
especi
attenu
vaccinia
viru
ankara
mva
vector
must
administ
second
immun
booster
wherea
first
inocul
prime
dna
capsid
viral
proteinexpress
vector
use
indiscrimin
promis
primeboost
combin
includ
dnapox
sfvpox
adenopox
current
avail
prevent
hiv
vaccin
fact
previous
describ
strategi
fail
one
singl
anim
protect
infect
experiment
model
tabl
trial
rais
controversi
whether
carri
sinc
experiment
result
immun
respons
induc
vaccin
prepar
limit
advanc
preclin
protocol
new
vaccin
prototyp
includ
develop
aventi
pasteur
uganda
use
canarypox
vector
express
viral
structur
protein
also
uganda
januari
saw
start
phase
trial
combin
dna
mva
strain
similar
phase
clinic
trial
sponsor
iavi
kavi
carri
kenya
unfortun
seem
unlik
assay
go
due
low
proport
individu
relev
immun
respons
elicit
vaccin
prepar
test
europ
eurovac
initi
clinic
phase
trial
use
poxviralbas
vaccin
nyvav
complet
juin
anoth
phase
trial
base
combin
dnanyvac
express
gag
pol
nef
subtyp
c
launch
also
juin
compar
assay
nyvacc
mvac
plan
latter
immunogen
gener
spain
nation
centr
biotechnolog
complet
updat
inform
situat
exist
vaccin
clinic
trial
avail
www
hvtnorgtrial
obtain
aid
vaccin
becom
global
enterpris
posit
increas
social
awar
diseas
financi
support
also
import
note
prioriti
given
vaccin
research
develop
new
approach
appear
time
know
much
pathogenesi
aid
ten
year
ago
nevertheless
must
rememb
demonstr
use
vaccin
long
expens
process
therefor
critic
aspect
problem
defin
strategi
criteria
differ
phase
vaccin
develop
type
vaccin
object
vaccin
experiment
design
anim
model
preclin
laboratori
analysi
phase
ii
trial
requir
infrastructur
phase
iii
trial
given
healthcar
social
polit
prioriti
subject
sometim
affect
seriou
concern
outsid
scientif
world
includ
social
pressur
intern
organ
countri
devast
epidem
financi
pressur
pharmaceut
compani
although
motiv
understand
given
sever
situat
attitud
also
distort
scientif
process
summar
key
question
search
aid
vaccin
scientist
doubt
efficaci
aid
vaccin
found
reason
difficulti
obtain
defin
steril
immun
retrovirus
analyz
mechan
action
vaccin
case
achiev
steril
immun
sinc
prevent
infect
rather
persist
microorgan
develop
diseas
germ
infect
immun
respons
prevent
spread
destroy
new
infect
cell
thu
help
erad
infect
case
siv
hiv
infect
know
first
inoculum
infect
take
place
short
period
time
import
reservoir
cell
lymphoid
system
becom
infect
initi
infect
cell
viru
replic
activ
other
remain
state
latenc
integr
proviru
genom
host
cell
therefor
despit
immun
respons
induc
vaccin
viru
persist
reservoir
replic
continu
particularli
controversi
area
final
object
vaccin
peopl
argu
possibl
induc
steril
immun
prevent
infect
enough
immun
respons
capabl
control
level
viral
replic
suffici
low
level
allow
immun
system
escap
huge
destruct
object
would
much
prevent
infect
attenu
way
infect
patient
becom
longterm
survivor
capabl
live
viru
anoth
area
debat
level
protect
must
reach
aid
vaccin
contrast
high
efficaci
protect
vaccin
vaccin
patient
differ
author
propos
partial
protect
rate
consid
suffici
reduct
final
object
attain
hiv
vaccin
arguabl
one
hand
doubt
attenu
infect
definit
phenomenon
mediumlong
term
anim
model
isol
case
infect
caus
defect
viru
viru
increas
virul
longterm
hand
although
true
establish
low
viral
load
primari
infect
good
prognost
factor
medium
term
guarante
patient
present
low
level
viral
load
vaccin
behav
longterm
survivor
fact
scientist
set
suffici
efficaci
vaccin
protect
level
also
critic
could
perhap
consid
realist
stanc
even
specif
preval
rate
specif
risk
group
vaccin
type
could
efficaci
know
real
impact
evolut
epidem
medium
term
must
forget
one
mechan
vaccin
efficaci
due
popul
epidemiolog
impact
decreas
preval
infect
consequ
reduc
possibl
transmit
germ
among
gener
popul
epidemiolog
impact
vaccin
would
exist
propos
protect
rate
author
suggest
variabl
among
subtyp
repres
import
obstacl
develop
univers
vaccin
ad
hoc
vaccin
manufactur
base
subtyp
circul
region
howev
new
vaccin
prototyp
use
viral
gene
env
nef
gag
pol
tat
target
much
lower
variabl
envelop
fact
differ
studi
show
immun
respons
induc
vaccin
specif
hiv
subtyp
capabl
act
subtyp
efficaci
differ
vaccin
evalu
efficaci
aid
vaccin
must
evalu
popul
high
rate
infect
order
obtain
signific
differ
control
group
vaccin
group
shortest
time
possibl
mean
almost
trial
carri
africa
southeast
asia
annual
seroconvers
rate
affect
area
approxim
popul
carri
trial
develop
countri
rais
seri
ethic
issu
essenti
studi
compli
ethic
requir
patient
right
guarante
vaccin
tri
must
satisfi
scientif
medic
requisit
potenc
safeti
necessari
medicin
tri
human
vaccin
trial
need
widerang
followup
infrastructur
guarante
patient
followup
therefor
essenti
develop
healthcar
structur
refer
center
follow
object
recruit
followup
volunt
extract
freez
storag
blood
accord
standard
procedur
assess
immunolog
paramet
lymphoid
popul
cytokin
product
neutral
antibodi
requisit
met
analysi
result
could
skew
andor
incomplet
thu
make
imposs
draw
conclus
one
demand
govern
vaccin
efficaci
free
access
vaccin
must
guarante
countri
evalu
carri
accord
ethic
guidelin
unaid
lifelong
antiretrovir
therapi
must
administ
person
infect
clinic
trial
import
problem
center
social
scientif
controversi
defin
requir
vaccin
prepar
must
fulfil
start
phase
iii
clinic
trial
journal
scienc
forum
seri
letter
prestigi
scientist
critic
invest
strategi
develop
aid
vaccin
initi
phase
iii
clinic
trial
strict
scientif
posit
defend
consist
data
efficaci
current
vaccin
prototyp
carri
phase
iii
clinic
trial
consequ
invest
concentr
basic
research
order
get
better
understand
mechan
protect
immun
respons
develop
new
relev
anim
model
face
stanc
humanist
posit
base
start
phase
iii
trial
catastroph
situat
develop
countri
counterargu
adequ
anim
model
anyway
necessari
carri
phase
studi
includ
phase
iii
human
obtain
definit
respons
despit
retic
pessim
larg
part
scientif
commun
gener
impress
phase
iii
trial
carri
import
rememb
cost
effort
involv
trial
requir
followup
patient
least
five
year
obtain
conclus
result
therefor
regard
aid
vaccin
live
difficult
time
huge
econom
invest
necessari
scientif
commun
gener
develop
evalu
vaccin
prototyp
imagin
anim
model
order
find
holi
grail
vaccin
refer
case
european
union
decid
start
program
phase
ii
clinic
trial
reduc
number
vaccin
prototyp
alreadi
gener
european
laboratori
invest
billion
euro
follow
year
requir
object
mind
develop
vaccin
research
center
propos
center
would
combin
critic
mass
investig
ii
sole
dedic
develop
prototyp
hiv
vaccin
iii
longterm
commit
academ
government
privat
institut
iv
suffici
resourc
v
continu
exchang
inform
collabor
privat
sector
consequ
polici
main
leader
organ
nih
iavi
anr
eu
gate
foundat
financ
vaccin
develop
center
would
coordin
work
prototyp
consid
interest
would
prepar
condit
good
manufactur
practic
use
human
would
enter
previous
defin
process
preclin
studi
phase
ii
iii
clinic
trial
prototyp
would
meet
minimum
requir
clinic
applic
would
mean
defin
criteria
also
involv
regulatori
author
fda
emea
develop
evalu
prototyp
also
requir
definit
immunolog
marker
must
use
evalu
potenti
efficaci
turn
would
mean
develop
standard
reproduc
trial
evalu
humor
cellular
respons
hiv
approv
laboratori
would
carri
immunolog
determin
lastli
necessari
healthcar
structur
set
carri
trial
clinic
phase
develop
countri
ethic
criteria
fulfil
trial
defin
given
larg
number
current
prototyp
tabl
applic
homogen
evalu
criteria
way
reach
consist
conclus
extrapol
situat
nevertheless
import
awar
search
full
unansw
question
fail
despit
effort
made
may
possibl
develop
vaccin
may
time
convey
terribl
possibl
societi
histori
vaccin
defin
word
empiric
success
intervent
save
mani
live
throughout
histori
medicin
vaccin
success
often
fruit
basic
empiric
howev
present
empiric
serv
basi
success
scientif
develop
aid
vaccin
conclud
recent
year
develop
aid
vaccin
chang
radic
due
differ
factor
devast
growth
epidem
social
awar
financi
invest
particular
better
understand
pathogenesi
new
element
enabl
us
face
challeng
ration
adequ
resourc
scientif
effort
combin
unpreced
solidar
allow
us
decid
whether
possibl
find
vaccin
hiv
whether
applic
suffici
curb
current
aid
pandem
